Tags : Facilitate

Bionano Genomics Acquires Lineagen to Facilitate the Clinical Adoption of

Shots: Lineagen to receive $9.6M consisting of 6,167,510 shares of Bionano’s common stock, ~ $1.7M in cash and assumption of ~$2.9M in liabilities. The acquisition complements Binano by adding leading cytogeneticists, genetic counselors, laboratory operations and billing experts, clinical commercialization experts, and payor contracts The acquisition expands Bionano’s Saphyr genome imaging platform by adding Lineagen’s […]Read More

Sanofi Collaborates with BARDA to Facilitate the Development of Coronavirus

Shots: Sanofi will leverage its previous development work for a SARS vaccine and utilize its recombinant DNA platform to accelerate the development of a vaccine candidate against coronavirus The SARS vaccine candidates that were developed by Protein Sciences (acquired by Sanofi in 2017) provides a head start in expediting a COVID-19 vaccine Additionally, in Dec’2019, […]Read More

Thermo Fisher Collaborates with NanoPin to Facilitate Infectious Diseases Diagnosis

Shots: The companies collaborated to develop highly sensitive liquid chromatography-mass spectrometry (LC-MS)-based workflows for advancing blood-based infectious disease detection technology  The collaboration leverages NanoPin’s diagnostic platform and Thermo Fisher’s LC-MS technology to develop clinical assays for infectious disease for determining infection stage and monitor patient response to treatment The collaboration may lead to a change […]Read More

Janssen Collaborates with BARDA to Facilitate the Development of Corona

Shots: Janssen partnered with BARDA to accelerate the development of its investigational coronavirus vaccine program. Both will partake to the research and development cost and mobilize resources to advance Janssen’s COVID-19 vaccine program BARDA to provide a fund to expedite the development of vaccine into P-I study with an option for additional funding to advance […]Read More

CRISPR Therapeutics and KSQ Therapeutics Cross Licenses their IP Rights

Shots: CRISPR to gain access to KSQ intellectual property (IP) for editing certain novel gene targets in its allogeneic oncology cell therapy programs while KSQ will get access to CRISPR’ IP for its autologous cell therapies including its existing eTIL cell franchise The agreement allows KSQ to leverage CRISPR’s editing technology in its eTIL programs, […]Read More